Surrogate Endpoints in Colorectal Cancer
1
Department of Oncology, McGill University and Montreal Centre for Experimental Therapeutics in Cancer, Sir Mortimer B. Davis–Jewish General Hospital, 3755 Cote St-Catherine Road, Montreal, QC H3T 1E2, Canada
2
BC Cancer Agency, Vancouver, BC, Canada
3
Notre Dame Hospital, Montreal, QC, Canada
4
St. Boniface General Hospital, Winnipeg, MN, Canada
5
The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada
6
Montreal Centre for Experimental Therapeutics in Cancer, Jewish General Hospital, and McGill University Department of Oncology, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2005, 12(4), 136-146; https://doi.org/10.3390/curroncol12040003
Submission received: 19 September 2005
/
Revised: 8 October 2005
/
Accepted: 25 October 2005
/
Published: 1 December 2005
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
There is ongoing debate about the criteria that are required for a new treatment to be approved for prescription and reimbursement and for clinicians to be convinced of that treatment’s true clinical utility [...]
Share and Cite
MDPI and ACS Style
Browman, G.; Shah, A.; Ayoub, J.; Wong, R.; Maroun, J.; Batist, G. Surrogate Endpoints in Colorectal Cancer. Curr. Oncol. 2005, 12, 136-146. https://doi.org/10.3390/curroncol12040003
AMA Style
Browman G, Shah A, Ayoub J, Wong R, Maroun J, Batist G. Surrogate Endpoints in Colorectal Cancer. Current Oncology. 2005; 12(4):136-146. https://doi.org/10.3390/curroncol12040003
Chicago/Turabian StyleBrowman, G., A. Shah, J. Ayoub, R. Wong, J. Maroun, and G. Batist. 2005. "Surrogate Endpoints in Colorectal Cancer" Current Oncology 12, no. 4: 136-146. https://doi.org/10.3390/curroncol12040003
